Delivery Order SPE2DR25D2003-SPE2DR26FR01R
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,049.61 to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Ingrezza 60 mg capsules (30-count units). The order represents a non-competitive, firm fixed-price delivery against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. Performance will be completed by December 3, 2025, with fulfillment occurring at the contractor's Conshohocken, Pennsylvania facility. Ingrezza is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) with a ceiling value of $7,748.14. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitive award to the prime contractor. The order is scheduled for completion by November 25, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Ingrezza 60 mg capsules (30-count units) under a firm fixed-price contract. The award, valued at $4,267.66, represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. This delivery order was competitively awarded with no set-aside designation and is scheduled for completion by December 30, 2025. The...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ingrezza 80 mg capsules (30-count units) with a contract ceiling value of $4,027.70. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The order is scheduled for completion by September 30, 2025, with fulfillment occurring at the vendor's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,874.06 to AmerisourceBergen Drug Corp for the supply of Ingrezza 40 mg capsules (30-count units) on November 24, 2025, with completion anticipated by December 16, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Ingrezza is a prescription medication used in the treatment of tardive dyskinesia, a...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Ingrezza 80 mg capsules (30-count units) under a firm fixed-price arrangement. The contract ceiling value is $12,083.10, with an ultimate completion date of October 17, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which holds a total value of...
- The Defense Logistics Agency awarded a $8,077.31 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ingrezza 60 mg capsules (30-count units). This competitively awarded, firm fixed-price contract is scheduled for completion by October 9, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with DLA....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ingrezza 80 mg capsules (30-count units) under a firm fixed price contract valued at $4,027.70, with an ultimate completion date of August 15, 2025. This non-competitive delivery order was issued on July 25, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The award represents a child order under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) valued at $3,874.06. This is a firm fixed-price delivery order with an ultimate completion date of December 30, 2025, and represents a non-competitive, non-set-aside award. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Ingrezza 40 mg capsules (30-count units) with a ceiling value of $3,676.12. This is a firm fixed-price delivery order with an ultimate completion date of October 7, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs...
- SPE2DR25D2003Indefinite Delivery Contract
- SPE2DR25D2003-SPE2DR26FR01RDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Ingrezza 60 mg capsules (30-count packages) valued at $4,267.66. This firm fixed-price delivery order, with an ultimate completion date of December 31, 2025, represents a non-competitive, non-set-aside award to the prime contractor. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as one of the nation's largest pharmaceutical distributors serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of medications and medical commodities to support military healthcare systems worldwide. Ingrezza, an antipsychotic medication used in the treatment of tardive dyskinesia, falls within the company's extensive portfolio of specialty pharmaceutical products delivered to federal customers including the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 12/8/25 |